explore -WSS

explore

author：Wikipedia 2025-09-03 14:35:18 - browse：5

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： App could help diagnose ear infections more accurately — and at home

WSS

NIH chief: government has fallen behind pharma on clinical trials

Neuroscience’s long legacy of racism

Physicians and social media: If you see something, say something?

White House drug czar issues call for 'recovery

Colonoscopy prep: Liquid

Gene editing the human germline: What are the risks?

focus

explore

knowledge

Activists slam private health insurers over coverage restrictions

Ohio still needs to do more to protect the right to abortion

Virginia high school admissions case could be legal follow

NIH chief: government has fallen behind pharma on clinical trials

Novavax promises a turnaround & Lilly roils the obesity market

Study suggests Covid rebound is far more common with Paxlovid than without

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Methadone treatment changes are coming. Do they go far enough?

Novavax promises a turnaround & Lilly roils the obesity market

5 to watch: Tech startups trying to solve health care's staffing crisis

hotspot

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Creating egg and sperm cells from stem cells raises ethical issues

Medical school prerequisites are outdated

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Carbon Health diabetes program, a test of data

Experimental asthma app from Apple and Anthem shows promise

hotspot

explore

focus

hotspot